BI's Pontiakos to discuss GMO-labelling at Engredea 2015

George will discuss the legislative landscape surrounding the use of GMOs

As part of a clean label education track being presented at Engredea 2015, George Pontiakos, President and CEO of BI Nutraceuticals, will discuss the legislative landscape surrounding the use of GMOs and the steps suppliers and manufacturers need to take to be prepared if GMO-labelling legislation eventually passes.

The session, 'Understanding the cost and complexity of GMO labelling,' will take place on Thursday (5 March) from 1:45–2:45 pm in the Marriott Orange County Ballroom 3/4, located adjacent to the Anaheim Convention Center.

During this session, Pontiakos will cover

• Defining 'What is GMO?'
• Sourcing non—GMO ingredients
• How GMO legislation will impact the supply chain: from both a cost and complexity perspective
• Testing parameters for non-GMO ingredients
• Why the industry must do a stronger job of interdicting GMO legislation before it gets traction
• If and when we will see government mandated GMO-labelling
• Should a raw material supplier be required to be non-GMO verified — or are they already doing that?
• What is the value of the non-GMO verified seal to a supplier?

As president and CEO, Pontiakos oversees all aspects of operations for BI Nutraceuticals’ west and east coast offices, and the Zuellig Group Nutrition and Ingredients, China. Pontiakos has held senior leadership positions at several leading consulting, medical services and technology companies including Monovasia, which he founded, Oluma, Lucent, Agere, Ortel, NetVantage and Timeplex. He has wide-ranging experience in scaling geographically dispersed, globally competitive companies to maximise their ability to successfully compete in the marketplace.

Companies

• BI Nutraceuticals